Artificial Blood Market, By Product Type (Hemoglobin-Based Oxygen Carriers, Perflurocarbon-Based Products, Recombinant Factors, Synthetic Platelets, Plasma Expanders, and Others), By Application (Anemia, Organ Transplant, Injuries & Trauma, Cardiovascular diseases, Maternal conditions, and Others), By End User (Hospitals, clinic, and Blood banks), Industry Trends, Estimation & Forecast, 2014-2025

Check Today's Best Price

$3500 Buy Now
The global Artificial Blood market is valued at XX billion US$ in 2018 is expected to reach 10.89 Billion US$ by the end of 2025, growing at a CAGR of 20.2% during 2019-2025.
  • Market Overview

    The global Artificial Blood market is valued at XX billion US$ in 2018 is expected to reach 10.89 Billion US$ by the end of 2025, growing at a CAGR of 20.2% during 2019-2025.

    Artificial Blood also called oxygen therapeutics, or hemoglobin-based oxygen carriers (HBOCs) offer the new and important life-saving medical treatments. Artificial Blood is a substance used to mimic and fulfill some functions of biological blood. Artificial Blood provides an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another. Artificial blood does not experience immunologic reactions, but they would face serious health problems if they received incompatible donated blood. Artificial blood can be safely shelved outside hospitals and then rapidly administered to patients in emergencies.

    Market Driver

    The shortage of transfusable blood stocks is boosting the global artificial blood market. For instance, as per the 2011 analysis from the national blood collection and utilization survey, the US could see a shortfall of around 4 million units of blood annually by 2030. About 6% of United States hospitals have reported that surgical procedures have had to be cancelled or postponed because of blood shortages. India fell short of 1.9 million units of blood in 2016-17, which is equivalent to 60 tankers, that could have aided more than 320,000 heart surgeries or 49,000 organ transplants. There has been an increasing shortage of 1.1 million units or 35 tankers of blood in 2015-16 when India had fallen 9% short of its 12 million target.

    Trauma death due to lack of availability of blood during operations and an increase in number of deaths by hemorrhagic shock globally are the driving factors of the global artificial blood market during the forecast period. For instance, according to the National center for biotechnology information in 2019, estimated that the annual incidence of the shock of any etiology is 0.3- 0.7 per 1000 cases with hemorrhagic shock being the most common in the intensive care unit.

    Market Restraint

    The side effect of Artificial Blood might hamper the global Artificial Blood market. For instance, the side effects include elevated blood pressure, abdominal discomfort, and a temporary reddish coloration of the eyes or skin. In some cases, it may increase the chances of a heart attack. The artificial blood is expensive.

    Segment Analysis

    Based on product type, the global Artificial Blood market is broadly segmented as Hemoglobin-Based Oxygen Carriers, Perflurocarbon-Based Products, Recombinant Factors, Synthetic Platelets, Plasma Expanders, and Others. In 2018 Hemoglobin-Based Oxygen Carriers is the dominant segment, and it accounts for approximately XX% of the market.

    Hemoglobin-based oxygen carriers (HBOC) is a type of artificial blood substitute made from molecules of hemoglobin (Hb), the oxygen-carrying protein in red blood cells that are either removed from cells and chemically modified during processing into a product or developed through genetic engineering. They have been studied as treatments for patients who have suffered a serious loss of blood due to injuries. Hemoglobin-based oxygen carriers (HBOCs) can potentially provide therapeutic oxygenation when blood or RBC are not available. Several of these HBOCs have undergone rigorous pre-clinical and clinical evaluation.

    The increasing clinical studies of Hemoglobin-based oxygen carriers (HBOC) by the researchers is boosting the global Artificial Blood market. For example, Researchers at Delhi University’s Department of Biochemistry, have developed laboratory-made hemoglobin, hemoglobin is a safe and portable blood substitute. It has multiple advantages like cheaper cost of production, long shelf life, blood group neutral, no associated risk of transmission of diseases and easy to store.

    Regional Analysis

    The global Artificial Blood market is segmented into North America, Europe, South America, Asia Pacific, Middle East, and Africa.

    North America is dominating the global Artificial Blood market, owing to the rise in trauma deaths due to excessive blood loss before the admission, increase in the prevalence of anemia and blood-related disorders across the region. For instance, According to Health 24 in 2016, more than 20,000 trauma deaths in the united states occur due to the blood before arriving at the treatment center.

    The increasing clinical studies of artificial blood by the researchers is boosting the North America Artificial Blood market. For example, Researchers develop artificial red blood cells for potential transfusion alternative ErythroMer, a nanotechnology-based artificial red blood cell product, emulated normal red blood cell interactions with oxygen and nitric oxide. ErythroMer is a blood substitute that a medic can carry in his or her pack and take it out, add water and inject it.

    The North America Artificial Blood market size was XX Billion USD in 2018, and it will be XX Billion USD in 2025, with a CAGR XX% from 2019 to 2025.

    Europe is the second-largest market for Artificial Blood in 2018, due to the increasing investment for artificial blood. For instance, on November 14, 2017, SpheriTech, a leading life science company, has received £100k for pioneering research project to develop artificial blood form Innovate UK. In Europe more than three million transfusions take place in the UK with the NHS Blood Transfusion Service collecting 1.7 million liters of blood in England and Wales which is given to around 500,000 patients.

    Competitive Analysis

    The major players include Alliance Pharmaceutical Corp., FluorO2 Therapeutics, Hemoglobin Oxygen Therapeutics LLC, Hemarina S.A, Kalocyte Inc., Jiangsu Nhwa Pharmaceutical Co., Ltd. (NuvOx Pharma LLC), Opk Biotech, Llc., Spheritech.

    The increasing investment by the companies for the development of artificial blood is boosting the global artificial blood market. For instance, in February 2019, Seattle Based medical technology company Healionics raised $3.8 million in funding to support the development of an artificial blood vessel called STARgraft for patients who undergo dialysis treatment.

    Global Artificial Blood Market

    • Consumption by Regions
      • North America
      • Europe
      • South America
      • Asia Pacific
      • The Middle East and Africa
    • Segment by Product Type
      • Hemoglobin-Based Oxygen Carriers
      • Perflurocarbon-Based Products
      • Recombinant Factors
      • Synthetic Platelets
      • Plasma Expanders
      • Others
    • Segment by Application
      • Anemia
      • Organ Transplant
      • Injuries & Trauma
      • Cardiovascular diseases
      • Maternal conditions
      • Others
    • Segment by End User
      • Hospitals
      • Clinic
      • Blood banks
    keyboard_arrow_up
  • Table of Content

    1. Market Introduction
    1.1. Executive Summary
    1.2. Market Definition
    1.3. Market Scope

    2. Research Methodology
    2.1. Primary Research
    2.2. Research Methodology
    2.3. Assumptions & Exclusions
    2.4. Secondary data sources

    3. Artificial Blood Market Overview
    3.1. Report Segmentation & Scope
    3.2. Key Market Trend
    3.3. Drivers
    3.3.1. The shortage of transfusable blood stocks
    3.4. Restraints
    3.4.1. The side effect of Artificial Blood
    3.5. Opportunity
    3.5.1. Increasing research activities of Artificial Blood
    3.6. Porter’s Five Forces Analysis
    3.6.1. Porter’s Five Forces Analysis
    3.7. Market Share Analysis

    4. Product Type Overview
    4.1. Introduction
    4.1.1. Market Size & Forecast
    4.2. Hemoglobin-Based Oxygen Carriers
    4.2.1. Market Size & Forecast
    4.3. Perflurocarbon-Based Products
    4.3.1. Market Size & Forecast
    4.4. Recombinant Factors
    4.4.1. Market Size & Forecast
    4.5. Synthetic Platelets
    4.5.1. Market Size & Forecast
    4.6. Plasma Expanders
    4.6.1. Market Size & Forecast
    4.7. Others
    4.7.1. Market Size & Forecast

    5. Application Overview
    5.1. Introduction
    5.1.1. Market Size & Forecast
    5.2. Anemia
    5.2.1. Market Size & Forecast
    5.3. Organ Transplant
    5.3.1. Market Size & Forecast
    5.4. Injuries & Trauma
    5.4.1. Market Size & Forecast
    5.5. Cardiovascular diseases
    5.5.1. Market Size & Forecast
    5.6. Maternal conditions
    5.6.1. Market Size & Forecast
    5.7. Others
    5.7.1. Market Size & Forecast

    6. End User Overview
    6.1. Introduction
    6.1.1. Market Size & Forecast
    6.2. Hospitals
    6.2.1. Market Size & Forecast
    6.3. Clinic
    6.3.1. Market Size & Forecast
    6.4. Blood banks
    6.4.1. Market Size & Forecast

    7. Artificial Blood Market Regional Overview
    7.1. Introduction
    7.1.1. Market Size & Forecast
    7.2. North America Artificial Blood Market
    7.2.1. North America Market Size & Forecast, By Country
    7.2.2. North America Market Size & Forecast, By Product Type
    7.2.3. North America Market Size & Forecast, By Application
    7.2.4. North America Market Size & Forecast, By End User
    7.2.5. U.S.
    7.2.5.1. Market Size and Forecast
    7.2.6. Canada
    7.2.6.1. Market Size and Forecast
    7.2.7. Mexico
    7.2.7.1. Market Size and Forecast
    7.3. Europe Artificial Blood Market
    7.3.1. Europe Market Size & Forecast, By Country
    7.3.2. Europe Market Size & Forecast, By Product Type
    7.3.3. Europe Market Size & Forecast, By Application
    7.3.4. Europe Market Size & Forecast, By End User
    7.3.5. Germany
    7.3.5.1. Market Size and Forecast
    7.3.6. France
    7.3.6.1. Market Size and Forecast
    7.3.7. UK
    7.3.7.1. Market Size and Forecast
    7.3.8. Italy
    7.3.8.1. Market Size and Forecast
    7.3.9. Spain
    7.3.9.1. Market Size and Forecast
    7.3.10. Rest of Europe
    7.3.10.1. Market Size and Forecast
    7.4. Asia-Pacific Artificial Blood Market
    7.4.1. Asia-Pacific Market Size & Forecast, By Country
    7.4.2. Asia-Pacific Market Size & Forecast, By Product Type
    7.4.3. Asia-Pacific Market Size & Forecast, By Application
    7.4.4. Asia-Pacific Market Size & Forecast, By End User
    7.4.5. Japan
    7.4.5.1. Market Size and Forecast
    7.4.6. China
    7.4.6.1. Market Size and Forecast
    7.4.7. Australia
    7.4.7.1. Market Size and Forecast
    7.4.8. India
    7.4.8.1. Market Size and Forecast
    7.4.9. South Korea
    7.4.9.1. Market Size and Forecast
    7.4.10. Rest of Asia-Pacific
    7.4.10.1. Market Size and Forecast
    7.5. South America Artificial Blood Market
    7.5.1. South America Market Size & Forecast, By Country
    7.5.2. South America Market Size & Forecast, By Product Type
    7.5.3. South America Market Size & Forecast, By Application
    7.5.4. South America Market Size & Forecast, By End User
    7.5.5. Brazil
    7.5.5.1. Market Size and Forecast
    7.5.6. Argentina
    7.5.6.1. Market Size and Forecast
    7.5.7. Rest of South America
    7.5.7.1. Market Size and Forecast
    7.6. Middle East & Africa Artificial Blood Market
    7.6.1. Middle East & Africa Market Size & Forecast, By Country
    7.6.2. Middle East & Africa Market Size & Forecast, By Product Type
    7.6.3. Middle East & Africa Market Size & Forecast, By Application
    7.6.4. Middle East & Africa Market Size & Forecast, By End User
    7.6.5. GCC Countries
    7.6.5.1. Market Size and Forecast
    7.6.6. Egypt
    7.6.6.1. Market Size and Forecast
    7.6.7. South Africa
    7.6.7.1. Market Size and Forecast
    7.6.8. Rest of Middle East & Africa
    7.6.8.1. Market Size and Forecast

    8. Company Profile
    8.1. FLUORO2 Therapeutics
    8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    8.1.2. FLUORO2 Therapeutics Product Category, Application, and Specification
    8.1.3. FLUORO2 Therapeutics Financial Performance (2016-2018)
    8.1.4. Main Business/Business Overview
    8.2. Kalocyte
    8.3. Hemarina
    8.4. North Field Laboratories
    8.5. Biopure Corporation
    8.6. Sangart Corporation
    8.7. Baxter
    8.8. Green Cross Corporation
    8.9. Alliance Pharmaceutical Corporation
    8.10. Alpha Therapeutic Corp.

    keyboard_arrow_up
    • The following manufacturers are covered:
      • Alliance Pharmaceutical Corp.
      • FluorO2 Therapeutics
      • Hemoglobin Oxygen Therapeutics LLC
      • Hemarina S.A
      • Kalocyte Inc.
      • Jiangsu Nhwa Pharmaceutical Co., Ltd. (NuvOx Pharma LLC)
      • Opk Biotech, Llc.
      • Spheritech
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS